Biotie To Combine With Synosia To Form A "Global Leader" In CNS Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
A Phase III drug for alcohol dependence and two Parkinson's disease therapies will head the pipeline of a proposed new European CNS drug development company.
You may also be interested in...
Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress
Finland's only publicly listed biotech, Biotie Therapies, is reviewing its licensing and M&A options in niche CNS areas as product milestone payments and equity investments expand its cash runway.
Roche Enters Hearing-Loss Space In Risk-Sharing Venture With Inception, Versant
The newly formed Inception 3 will work to bring small molecule candidates for hearing loss, based on technology licensed from Stanford University, to IND-filing stage, at which point Roche will have the option to buy out the program.
Biotie Buys Newron In Pain Deal; Price Brings Little Relief
Biotie's acquisition of pain-focused Newron for €38 million upfront reflects the trouble Newron was in - and the riskiness of the field.